HZNP logo

Horizon Therapeutics Public Limited (HZNP) Stock

Profile

Sector:

Healthcare

Country:

Ireland

IPO:

28 July 2011

Indexes:

Not included

Description:

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Nov 02, 2023

Recent annual earnings:

Mar 01, 2023
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

13 Dec '22 Wells Fargo
Equal-Weight
13 Dec '22 SVB Leerink
Market Perform
13 Dec '22 Guggenheim
Neutral
13 Dec '22 BMO Capital
Market Perform
12 Dec '22 Stifel
Hold
07 Dec '22 Piper Sandler
Overweight
03 Nov '22 SVB Leerink
Outperform
01 Nov '22 HC Wainwright & Co.
Neutral
25 Oct '22 Piper Sandler
Overweight
04 Aug '22 UBS
Neutral

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Horizon Therapeutics Shares Surge As FTC Postpones Challenge to Merger
Horizon Therapeutics Shares Surge As FTC Postpones Challenge to Merger
Horizon Therapeutics Shares Surge As FTC Postpones Challenge to Merger
HZNP
Investopedia28 August 2023

Horizon Therapeutics (HZNP) shares jumped more than 5.5% in early trading Monday after the FTC said it would suspend its challenge to Amgen's (AMGN) acquisition of the drug maker.

Horizon (HZNP) Up as FTC Pauses Acquisition by Amgen Lawsuit
Horizon (HZNP) Up as FTC Pauses Acquisition by Amgen Lawsuit
Horizon (HZNP) Up as FTC Pauses Acquisition by Amgen Lawsuit
HZNP
Zacks Investment Research28 August 2023

The Federal Trade Commission suspends its ongoing lawsuit to block Horizon's (HZNP) acquisition by Amgen until Sep 18, 2023. The company's stock rises 5.8% in response.

Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales
Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales
Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales
HZNP
Zacks Investment Research09 August 2023

Horizon (HZNP) reports better-than-expected second-quarter results, beating both earnings and sales estimates, with the top-line key contributors being Krystexxa and Uplizna.

Horizon Therapeutics (HZNP) Surpasses Q2 Earnings and Revenue Estimates
Horizon Therapeutics (HZNP) Surpasses Q2 Earnings and Revenue Estimates
Horizon Therapeutics (HZNP) Surpasses Q2 Earnings and Revenue Estimates
HZNP
Zacks Investment Research08 August 2023

Horizon Therapeutics (HZNP) came out with quarterly earnings of $1.20 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.07 per share a year ago.

Compared to Estimates, Horizon Therapeutics (HZNP) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, Horizon Therapeutics (HZNP) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, Horizon Therapeutics (HZNP) Q2 Earnings: A Look at Key Metrics
HZNP
Zacks Investment Research08 August 2023

The headline numbers for Horizon Therapeutics (HZNP) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Horizon's (HZNP) Daxdilimab Fails to Meet Goal in Lupus Study
Horizon's (HZNP) Daxdilimab Fails to Meet Goal in Lupus Study
Horizon's (HZNP) Daxdilimab Fails to Meet Goal in Lupus Study
HZNP
Zacks Investment Research24 July 2023

Horizon (HZNP) fails to meet the primary endpoint in the mid-stage study of evaluating daxdilimab in the treatment of systemic lupus erythematosus.

Why Is Horizon Therapeutics (HZNP) Down 9% Since Last Earnings Report?
Why Is Horizon Therapeutics (HZNP) Down 9% Since Last Earnings Report?
Why Is Horizon Therapeutics (HZNP) Down 9% Since Last Earnings Report?
HZNP
Zacks Investment Research02 June 2023

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?

Why Horizon Therapeutics Stock Is Crashing Today
Why Horizon Therapeutics Stock Is Crashing Today
Why Horizon Therapeutics Stock Is Crashing Today
HZNP
The Motley Fool16 May 2023

Last December, Amgen and Horizon agreed to a $27.8 billion buyout agreement. This proposed deal is now in doubt following a report that the FTC plans on challenging the takeover in federal court.

HZNP Stock Alert: Why Is Horizon Therapeutics Plunging Today
HZNP Stock Alert: Why Is Horizon Therapeutics Plunging Today
HZNP Stock Alert: Why Is Horizon Therapeutics Plunging Today
HZNP
InvestorPlace16 May 2023

Horizon Therapeutics (NASDAQ: HZNP ) stock is sinking 18% this morning. The Federal Trade Commission (FTC) is reportedly attempting to block the drug maker's proposed merger with Amgen (NASDAQ: AMGN ).

Why These 2 Large-Cap Stocks Dropped 10%-Plus on Tuesday
Why These 2 Large-Cap Stocks Dropped 10%-Plus on Tuesday
Why These 2 Large-Cap Stocks Dropped 10%-Plus on Tuesday
HZNP
The Motley Fool16 May 2023

The Dow and S&P 500 moved lower Tuesday morning. Sea Limited shares fell as the company's video game segment failed to meet expectations.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of Horizon Therapeutics Public Limited?
  • What is the ticker symbol for Horizon Therapeutics Public Limited?
  • Does Horizon Therapeutics Public Limited pay dividends?
  • What sector is Horizon Therapeutics Public Limited in?
  • What industry is Horizon Therapeutics Public Limited in?
  • What country is Horizon Therapeutics Public Limited based in?
  • When did Horizon Therapeutics Public Limited go public?
  • Is Horizon Therapeutics Public Limited in the S&P 500?
  • Is Horizon Therapeutics Public Limited in the NASDAQ 100?
  • Is Horizon Therapeutics Public Limited in the Dow Jones?
  • When was Horizon Therapeutics Public Limited's last earnings report?
  • When does Horizon Therapeutics Public Limited report earnings?
  • Should I buy Horizon Therapeutics Public Limited stock now?

What is the primary business of Horizon Therapeutics Public Limited?

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

What is the ticker symbol for Horizon Therapeutics Public Limited?

The ticker symbol for Horizon Therapeutics Public Limited is NASDAQ:HZNP

Does Horizon Therapeutics Public Limited pay dividends?

No, Horizon Therapeutics Public Limited does not pay dividends

What sector is Horizon Therapeutics Public Limited in?

Horizon Therapeutics Public Limited is in the Healthcare sector

What industry is Horizon Therapeutics Public Limited in?

Horizon Therapeutics Public Limited is in the Drug Manufacturers - General industry

What country is Horizon Therapeutics Public Limited based in?

Horizon Therapeutics Public Limited is headquartered in Ireland

When did Horizon Therapeutics Public Limited go public?

Horizon Therapeutics Public Limited's initial public offering (IPO) was on 28 July 2011

Is Horizon Therapeutics Public Limited in the S&P 500?

No, Horizon Therapeutics Public Limited is not included in the S&P 500 index

Is Horizon Therapeutics Public Limited in the NASDAQ 100?

No, Horizon Therapeutics Public Limited is not included in the NASDAQ 100 index

Is Horizon Therapeutics Public Limited in the Dow Jones?

No, Horizon Therapeutics Public Limited is not included in the Dow Jones index

When was Horizon Therapeutics Public Limited's last earnings report?

Horizon Therapeutics Public Limited's most recent earnings report was on 2 November 2023

When does Horizon Therapeutics Public Limited report earnings?

The date for Horizon Therapeutics Public Limited's next earnings report has not been announced yet

Should I buy Horizon Therapeutics Public Limited stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions